Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation. 1995

Y T Wachtfogel, and C E Hack, and J H Nuijens, and C Kettner, and T M Reilly, and R M Knabb, and R Bischoff, and H Tschesche, and H Wenzel, and U Kucich
Sol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia 19140.

Cardiopulmonary bypass causes hemorrhagic complications and initiates a biochemical and cellular "whole body inflammatory response." This study investigates whether a variety of selective inhibitors of the contact pathway of intrinsic coagulation modulate complement and neutrophil activation during simulated extracorporeal circulation. After 60 min of recirculation in the presence of the slow tight-binding boronic acid inhibitor, Bz-Pro-Phe-boroArg-OH (10.7 microM), complete inhibition of kallikrein-C1-inhibitor complex formation and marked inhibition of C1-C1-inhibitor complex formation and the release of human neutrophil elastase were observed. Arg15-aprotinin (3.1 microM), Ala357,Arg358 alpha 1-antitrypsin (2.6 microM), and soybean trypsin inhibitor (48.0 microM) either completely or partially inhibited the generation of kallikrein-C1-inhibitor complexes but were less effective inhibitors of human neutrophil elastase release. The second-order rate constants for the inhibition of kallikrein in purified systems are consistent with the order of effectiveness of the inhibitors in blocking human neutrophil elastase release in heparinized blood. Our results suggest that low-molecular-weight selective inhibitors of kallikrein may be effective agents in the attenuation of the contact-mediated inflammatory response in cardiopulmonary bypass.

UI MeSH Term Description Entries
D007610 Kallikreins Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77). Kallikrein,Kininogenase,Callicrein,Dilminal,Kallidinogenase,Kalliginogenase,Kallikrein A,Kallikrein B',Kallikrein Light Chain,Kinin-Forming Enzyme,Padutin,alpha-Kallikrein,beta-Kallikrein,beta-Kallikrein B,Enzyme, Kinin-Forming,Kinin Forming Enzyme,Light Chain, Kallikrein,alpha Kallikrein,beta Kallikrein,beta Kallikrein B
D007611 Aprotinin A single-chain polypeptide derived from bovine tissues consisting of 58 amino-acid residues. It is an inhibitor of proteolytic enzymes including CHYMOTRYPSIN; KALLIKREIN; PLASMIN; and TRYPSIN. It is used in the treatment of HEMORRHAGE associated with raised plasma concentrations of plasmin. It is also used to reduce blood loss and transfusion requirements in patients at high risk of major blood loss during and following open heart surgery with EXTRACORPOREAL CIRCULATION. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995) BPTI, Basic Pancreatic Trypsin Inhibitor,Basic Pancreatic Trypsin Inhibitor,Bovine Kunitz Pancreatic Trypsin Inhibitor,Kallikrein-Trypsin Inactivator,Kunitz Pancreatic Trypsin Inhibitor,Trypsin Inhibitor, Basic, Pancreatic,Trypsin Inhibitor, Kunitz, Pancreatic,Antilysin,Bovine Pancreatic Trypsin Inhibitor,Contrical,Contrykal,Dilmintal,Iniprol,Kontrikal,Kontrykal,Pulmin,Traskolan,Trasylol,Zymofren,Inactivator, Kallikrein-Trypsin,Kallikrein Trypsin Inactivator
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D010196 Pancreatic Elastase A protease of broad specificity, obtained from dried pancreas. Molecular weight is approximately 25,000. The enzyme breaks down elastin, the specific protein of elastic fibers, and digests other proteins such as fibrin, hemoglobin, and albumin. EC 3.4.21.36. Elastase,Pancreatopeptidase,Elastase I,Pancreatic Elastase I,Elastase I, Pancreatic,Elastase, Pancreatic
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D001896 Boron Compounds Inorganic or organic compounds that contain boron as an integral part of the molecule. Borides,Compounds, Boron

Related Publications

Y T Wachtfogel, and C E Hack, and J H Nuijens, and C Kettner, and T M Reilly, and R M Knabb, and R Bischoff, and H Tschesche, and H Wenzel, and U Kucich
November 1983, The Journal of clinical investigation,
Y T Wachtfogel, and C E Hack, and J H Nuijens, and C Kettner, and T M Reilly, and R M Knabb, and R Bischoff, and H Tschesche, and H Wenzel, and U Kucich
January 1987, Blood,
Y T Wachtfogel, and C E Hack, and J H Nuijens, and C Kettner, and T M Reilly, and R M Knabb, and R Bischoff, and H Tschesche, and H Wenzel, and U Kucich
January 2003, Kidney & blood pressure research,
Y T Wachtfogel, and C E Hack, and J H Nuijens, and C Kettner, and T M Reilly, and R M Knabb, and R Bischoff, and H Tschesche, and H Wenzel, and U Kucich
October 2003, The Annals of thoracic surgery,
Y T Wachtfogel, and C E Hack, and J H Nuijens, and C Kettner, and T M Reilly, and R M Knabb, and R Bischoff, and H Tschesche, and H Wenzel, and U Kucich
January 1983, Annals of the New York Academy of Sciences,
Y T Wachtfogel, and C E Hack, and J H Nuijens, and C Kettner, and T M Reilly, and R M Knabb, and R Bischoff, and H Tschesche, and H Wenzel, and U Kucich
June 2002, The Thoracic and cardiovascular surgeon,
Y T Wachtfogel, and C E Hack, and J H Nuijens, and C Kettner, and T M Reilly, and R M Knabb, and R Bischoff, and H Tschesche, and H Wenzel, and U Kucich
March 2011, Expert opinion on therapeutic patents,
Y T Wachtfogel, and C E Hack, and J H Nuijens, and C Kettner, and T M Reilly, and R M Knabb, and R Bischoff, and H Tschesche, and H Wenzel, and U Kucich
August 2016, Journal of enzyme inhibition and medicinal chemistry,
Y T Wachtfogel, and C E Hack, and J H Nuijens, and C Kettner, and T M Reilly, and R M Knabb, and R Bischoff, and H Tschesche, and H Wenzel, and U Kucich
March 2011, Bioorganic & medicinal chemistry letters,
Y T Wachtfogel, and C E Hack, and J H Nuijens, and C Kettner, and T M Reilly, and R M Knabb, and R Bischoff, and H Tschesche, and H Wenzel, and U Kucich
December 2021, Journal of enzyme inhibition and medicinal chemistry,
Copied contents to your clipboard!